GlycoEra

Schlieren, Switzerland

GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.

$130.0M raised

May 2025

Series B

Top Investors

Catalio Capital Management5AM VenturesNovo HoldingsSofinnova PartnersAgent Capital

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has GlycoEra raised?

GlycoEra has raised $130.0M in total funding. The most recent round was Series B. The last funding was announced in May 2025.

Who are GlycoEra's investors?

GlycoEra's investors include Catalio Capital Management, 5AM Ventures, Novo Holdings, Sofinnova Partners, Agent Capital.

Where is GlycoEra headquartered?

GlycoEra is headquartered in Schlieren, Switzerland.

What does GlycoEra do?

GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.

What stage is GlycoEra at?

GlycoEra is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 27, 2025.

MLA

"GlycoEra — Funding & Investors." VCBacked, May 27, 2025, https://www.vcbacked.co/company/glycoera. Accessed June 4, 2026.

APA

VCBacked. (2025). GlycoEra — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/glycoera

Wikipedia (cite web)

{{cite web |title=GlycoEra — Funding & Investors |url=https://www.vcbacked.co/company/glycoera |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 27, 2025.